Clarivate Identifies 13 Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

2 minutes read

Clarivate Identifies 13 Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

In a groundbreaking revelation, Clarivate Plc, a global leader in providing trusted intelligence, has unveiled its highly anticipated annual Drugs to Watch™ report. This comprehensive report delves into predictive analysis, identifying 13 potential blockbuster drugs and game-changers set to revolutionize the pharmaceutical landscape by 2029.

These innovative therapeutics, spanning various medical conditions, exhibit the potential for remarkable commercial and clinical success.

Key Highlights:

1. Therapeutic Advancements: The report emphasizes therapeutic advancements for ailments such as sickle cell disease, respiratory syncytial virus (RSV), breast cancer, Crohn’s disease, and more, poised to advance patient health despite challenges faced by life science companies.

2. Global Impact: The 13 new-to-market drugs, projected to launch in 2024, are anticipated to achieve blockbuster status or deliver game-changing benefits to patients worldwide by 2029.

3. Chronic Disease Market in China: The report spotlights the growing chronic disease market in Mainland China, highlighting seven drugs expected to achieve $1 billion blockbuster status by 2029 or significantly impact Chinese patients in need of better treatment options.

Insights from Clarivate

Mike Ward, Global Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, expressed optimism about the biopharma sector’s robust fundamentals. He emphasized the role of new technologies in fueling medical advancements, and providing treatment options for previously unmet needs.

Transformational Innovations in 2024

The year 2024 is anticipated to be transformative for the pharmaceutical industry, marked by innovations such as antibody-drug conjugates and AI/machine learning. These modalities, underpinned by scientific breakthroughs, are achieving clinical successes and addressing the needs of patients with limited treatment options.

Challenges in the Sector

Despite the industry’s positive trajectory, external factors such as government initiatives to contain healthcare costs, sustained high capital costs, and global geopolitical disputes are impacting investor appetites for the sector.

The 2024 Drugs to Watch

The report highlights the following drugs as potential game-changers:

1. Aflibercept (high dose; EYLEA® HD) – Bayer and Regeneron Pharmaceuticals Inc.

2. Budesonide (TARPEYO®/Kinpeygo®/Nefecon) – Calliditas Therapeutics AB, Everest Medicines, and STADA Arzneimittel AG.

3. Datopotamab deruxtecan (Dato-DXd) – AstraZeneca and Daiichi Sankyo.

4. Efanesoctocog alfa (ALTUVIIIO™/BIVV001) – Sanofi (Bioverativ Therapeutics Inc) and Swedish Orphan Biovitrum AB (Sobi®).

5. Ensifentrine (RPL554) – Verona Pharma.

6. Exagamglogene autotemcel (CASGEVY™ /exa-cel) and lovotibeglogene autotemcel (LYFGENIA™/lovo-cel/formerly LentiGlobin™) – CRISPR Therapeutics, Vertex Pharmaceuticals Inc, and Bluebird Bio.

7. Mirikizumab (Omvoh™/ LY-3074828) – Eli Lilly and Company.

8. Niraparib + abiraterone acetate (AKEEGA™) – Johnson & Johnson Innovative Medicine.

9. RSVpreF (ABRYSVO™/PF-06928316) and RSVpreF3 (AREXVY/GSK-3844766A) – Pfizer Inc (ABRYSVO) and GSK plc (AREXVY).

10. Talquetamab (TALVEY™) – Johnson & Johnson Innovative Medicine.

These drugs encompass a diverse range of therapeutic areas, promising to redefine patient outcomes and contribute to the evolving landscape of pharmaceutical interventions.

Pharmaceutical industry stakeholders and healthcare professionals anticipate a transformative year, as the healthcare industry is poised to witness the impact of these innovative drugs on patient care and the global healthcare landscape.